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Abstract
Metabolic substrate utilization of the human failing heart is an area of controversy. The purpose of this study is to directly
quantify myocardial substrate utilization in moderately severe heart failure, type 2 diabetes and healthy controls using
simultaneous coronary sinus and arterial blood sampling. Patients with heart failure (n=9, mean NYHA 2.760.5), with type 2
diabetes (n=5) and with normal heart function (n=10) were studied after an overnight fast in connection with
electrophysiological investigations/treatments. A systemic infusion of [
2H2]palmitate allowed for the calculation of
absolute palmitate extraction across the heart. Blood samples were analysed for non-esterified fatty acids, triacylglycerol,
glycerol, glucose, pyruvate, lactate, 3-hydroxybutyrate, and blood gases after simultaneous sampling of arterial and
coronary sinus blood. Arterio-coronary sinus metabolite concentration differences and fractional extractions for all
substrates were similar between the groups. The absolute NEFA uptakes assessed by [
2H2]palmitate extraction were also
similar between the groups. Using direct measurements of metabolic substrate uptake by arterio-venous difference
technique, the compensated human failing heart does not appear to have reduced myocardial fatty acid uptake.
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Introduction
The healthy human myocardium displays a phenomenal ability
to switch from fatty acid utilization in the fasted state to glucose
utilization in response to insulin [1]. However, if glucose utilization
is forced this enhances myocardial energy efficiency is demon-
strated; not only is less oxygen consumed per ATP generated, the
mechanical output for a given quantity of oxygen consumption is
also increased [2].
Substrate utilization of the failing heart has recently been
reviewed [3]. Abundant data suggest that rodent models of heart
failure show increased myocardial glucose dependence whereas
the literature is conflicting for dogs and humans. Also, patterns of
gene expression would support a preference towards glucose
utilization in failing compared with normal human hearts [4].
Whether a shift towards glucose utilization is an adaptation to
more efficiently generate ATP, or a maladaption with restrictions
in the flexibility of substrate utilization, is still unclear [5].
The evidence for a shift towards glucose utilization in human
heart failure arises from non-invasive monitoring using PET
imaging of labelled glucose and palmitic acid moieties. Davila-
Roman and colleagues [6] compared substrate utilization in
controls and patients with idiopathic dilated cardiomyopathy after
serial infusion of
15O-water (blood flow),
11C-acetate (myocardial
oxygen consumption),
11C-glucose (myocardial glucose uptake)
and
11C-palmitic acid (myocardial fatty acid uptake and oxidation)
finding a shift away from fatty acid uptake/oxidation towards
glucose uptake in failing hearts. An earlier study by Taylor et al.
[7] compared non-metabolizable glucose (
18F-deoxyglucose) and
palmitic acid (
18F-6-thia-heptadecanoic acid) with a conclusion
essentially contradictory to Davila-Roman et al. [6], but this study
lacks matched controls. Also, Wallhaus and colleagues have used
non-metabolizable substrates in a study of heart failure in which
carvedilol was used therapeutically to improve cardiac function
[8]. They observed a reduction in fatty acid uptake in combination
with a non-significant increase in glucose uptake as heart function
improved. The reason for these conflicting results is not clear but it
could depend on differences in patient characteristics, including
degree and nature of cardiomyopathy, or differences in metabolic
background of the patients. It is also been suggested that the
complexity of using the non-metabolizable substrates in PET
scanning is not fully resolved [9].
An alternative and classic approach to estimate metabolic
substrate utilization of the human heart is to establish arterio-
venous gradients of substrates by sampling coronary sinus blood.
Although this has been attempted in a meticulous study [10], the
data on fatty acid uptake appear to be artificially low, presumably
for methodological reasons and there is no estimation of
triglyceride extraction. Based on the abundant data in rodents,
and some evidence in humans [6], we hypothesized that failing
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preference for glucose in the fasted state i.e. when fatty acids
should be preferentially used. We recruited well-matched heart
failure, control and type 2 diabetes (T2DM) groups in whom we
established coronary sinus sampling simultaneously with a
constant intravenous infusion of [
2H2]palmitate for specific
quantification of fatty acid uptake and other metabolic substrates.
Methods
Study population
The study population consisted a group with heart failure
(n=9), T2DM (n=5) and normal heart function (n=10). The
study was conducted prior to invasive electrophysiological
investigation/treatment due to a case history of arrhythmia. Eight
patients in the heart failure group had idiopathic dilated
cardiomyopathy, and one had ischemic cardiomyopathy. Mean
NYHA class of the heart failure group was 2.760.5. Oral
administrations of b-adrenoreceptor blockers, were withheld at
least 48 hours before the study. The control group consisted of ten
patients with normal left ventricular function but a case history of
either supra-ventricular tachycardia or paroxysmal atrial flutter.
All participants showed normal sinus rhythm during investigation.
The T2DM group consisted of three patients with heart failure
and none of them were taking any oral anti-diabetic agent or
insulin therapy.
All patients underwent a complete cardiac evaluation, including
a history, physical examination and echocardiogram. The protocol
was approved by the Oxfordshire Research Ethics Committee C
and all participants gave written informed consent before the
investigation.
Investigations
All investigations were made following an 8-hour or overnight
fast. Coronary sinus catheters were placed into coronary sinus via
a femoral or a jugular vein approach aided by fluoroscopy.
Arterial blood samples were from the femoral artery. All blood
samples were taken before arrhythmia induction, ablation or
pacemaker lead implant. No antiarrhythmic drugs or isoproterenol
were administered before sampling. None of the patients had
received heparin prior to, or during blood sampling. Patients
received oxygen at 3–4 L/min through a face masks during the
study.
A constant infusion of [
2H2]palmitate (0.04 mmol/kg/min)
dissolved in 4.5% human serum albumin was started 30 min
prior to blood sampling. Three blood samples spaced 5 min were
taken simultaneously from the arterial line and the coronary sinus
and immediately transferred into heparinized tubes on ice. Plasma
was separated within an hour.
Chemical and stable isotope determinations
Quantification in plasma of non-esterified fatty acids, triacyl-
glycerol, glycerol, glucose, pyruvate, lactate and 3-hydroxybuty-
rate as well as the determination of [
2H2]palmitate enrichment was
done exactly as described elsewhere [11]. Absolute non-esterified
fatty acid extraction was calculated by knowing the proportion of
palmitate to the total fatty acids. Blood gases were determined in
triplicate (GEM Premier3000, Instrumentation Laboratory, Lex-
ington, MA). BNP was analysed on a Siemens ADVIA Centaur
(Siemens HealthcareDiagnostics, Frimley, UK) using an immuno-
assay with a coefficient of variation of 6.3%.
Substrate extraction was expressed in relation to O2 consump-
tion using the Oxygen Extraction Ratio % (OER%) as described
before [12] The potential O2 consumption resulting from uptake
of each substrate was expressed as a percentage of total myocardial
O2 consumption. The sum of OERs for the major myocardial
substrates was greater than 100% (indicating that all substrates
were not completely oxidized). To calculate the percentage
contributions of different substrates to myocardial oxidative
metabolism, these were adjusted to a total of 100%.
Statistics
Data are presented as means6standard deviation using
conventional methods (SPSS version 17) except for variables
without normal distribution where median and range are shown.
Skewness was tested using the Shapiro-Wilk normality test.
Pearson correlation coefficients were calculated and for skewed
variables Spearman Rank correlation coefficients were used.
Statistical significances between groups were performed using
Students unpaired t-test or Mann-Whitney U-test.
Results
Age, body mass index, blood pressure and heart rate were
comparable between the three groups (Table 1). A considerable
elevation of plasma BNP together with lower echocardiographic-
determined left ventricular ejection fraction (LVEF) verified the
presence of heart failure. There was no significant difference in
baseline plasma concentrations of metabolic substrates except higher
glucose and lactate concentrations in patients in the T2DM group.
Arterio-coronary sinus concentration differences of metabolites
and fractional extractions were similar between the groups for all
substrates except for lactate extraction, which was slightly higher
in the T2DM group (Table 1 and 2). As there were no differences
in oxygen extraction and little or no difference in proportional
Table 1. Baseline description of heart failure, control and
type 2 diabetes groups.
Heart failure
n=9
Control
n=10
Type 2 diabetes
n=5
Gender (M/F) 7/2 4/6 5/0
#
Age (years) 53694 7 614 5666
Body mass index (kg/m
2)3 0 672 7 652 8 63
Systolic BP (mmHg) 121612 127623 118622
Diastolic BP (mmHg) 71614 76614 75622
Heart rate (beats/min) 77615 75614 65615
LVEF (%) 32616
$ 59654 9 621
BNP (pg/ml) 128 (22–432) * 16 (3–17) 41 (2–656)
Insulin (mU/l) 15691 1 651 8 611
NEFA (mmol/l) 7056252 7056256 6466152
Triacylglycerol (mmol/l) 0.9460.72 1.1860.63 1.0860.29
Glucose (mmol/l)) 5.260.8
{ 5.360.4 7.060.7 *
Pyruvate (mmol/l) 67634 46620 56628
Lactate (mmol/l) 5246235 5466140 8026298
#
3-hydroxybutyrate (mmol/l) 2326208 1776149 112671
Glycerol (mmol/l) 84640 77631 85651
Values are mean6SD except for BNP which is shown as median (range).
#p,0.05 vs control,
*p ,0.01 vs control,
$p,0.001 vs control,
{p,0.01 vs DM using Student’s t-test, except for BNP where Mann-Whitney U-
test was used.
doi:10.1371/journal.pone.0007533.t001
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metabolites did not show any differences between the groups
(Fig. 1).
Arterial and coronary sinus tracer to trace ratio (TTR) of
[
2H2]palmitate were comparable between the three sampling
occassions, which implies steady state. The TTR was consistently
15–20% lower in venous blood. The absolute non-esterified fatty
acid plasma extraction assessed by isotopic tracer extraction was
also similar between the three groups (140640, 167663,
148661 mmol/l, heart failure, T2DM and control group,
respectively (all ns)).
The fractional extraction of non-esterified fatty acids (r=0.76,
p,0.001), pyruvate (r=0.82, p,0.001), lactate (r=0.68,
p,0.001) and 3-hydroxybutyrate (r=0.98 p,0.001), were
positively correlated with the arterial concentration for each
substrate. In contrast, triacylglycerol and glucose extractions were
unrelated to their respective arterial concentrations. Neither
extractions of non-esterified fatty acids, [
2H2]palmitate or of
glucose showed any relationship to LVEF or plasma BNP levels.
Discussion
We hypothesized to that failing hearts would display signs of
reduced fatty acid uptake in favour of glucose, but there was no
difference in the fractional extraction between fatty acid and
glucose comparing healthy and failing hearts. As outlined in the
Introduction, and also in a recent review [3], studies in animals
provide a very consistent view that failing hearts have reduced
fatty acid uptake whereas the few studies in humans are largely
conflicting. It has also been suggested that the stage of heart failure
is of importance as a switch towards glucose utilization is
particularly easily observed in models of severe heart failure [3].
Our findings are in apparent contrast to those of Davila-Roman
et al. [6] who found a shift towards glucose utilization in seven
rather young patients with severe idiopathic dilated cardiomyop-
athy. Differences in clinical staging, the (in)comparability of
control groups, and perhaps not least differences in technology
could explain discrepancies between the studies. Of note, the heart
failure and control groups were comparable for body mass index
and fasting concentration of non-esterified fatty acids and blood
glucose. Also, seemingly in contrast to Davila-Roman et al. [6],
Wallhaus and colleagues [8] reported on the fatty acid and glucose
utilization in considerably older patients undergoing significant
improvements in heart function by carvedilol medication. The
improvement (LVEF increasing from 25 to 37%) was linked to
reduced fatty acid utilization but no apparent change in glucose
uptake. However, Blain et al. performed direct measurements of
metabolic substrate utilization in control and congestive heart
failure patients by coronary sinus sampling showing that the
respiratory quotient across the heart was close to 0.7 in both
controls and patients [10] lending support to the notion of
predominant fat oxidation in severe congestive heart disease.
We found a strong correlation between systemic non-esterified
fatty acid concentrations and the uptake of fatty acids by the heart.
Accordingly, background metabolic state may significantly affect
the heart’s preference for substrate, but in this study we were
fortunate to observe extremely well-balanced background meta-
bolic profiles between the groups.
The specific fatty acid uptake was quantified by isotope dilution
technique and we were intrigued to find a 15–20% reduction in
TTR of [
2H2]palmitate/palmitate across the heart. This can only
be the consequence of a dilution but the exact origin of the diluting
fatty acids is unclear. A likely source is palmitate release from the
epicardial adipose tissue. Epicardial fat may directly modulate the
myocardium throughout vasocrine or/and paracrine pathways.
The absence of fascial boundaries between the myocardium and
the epicardial fat, supports the hypothesis of direct interconnection
between the epicardial fat and the myocardium. The epicardial fat
and the myocardium share the same microcirculation, including
venous and arterial circulation [13].
Limitations of this study are the absence of blood flow
measurements as well as substrate oxidation measurements. It
would also have been of significant interest to observe the substrate
utilization changes in response to insulin stimulation.
Although this study does not settle the issue of whether altered
metabolic substrate utilization could be a cause or an adaptive
consequence in heart failure it shows that the human moderately
failing heart is not clearly prone to glucose utilization when this is
quantified by direct methods, and it underscores the importance of
robust methodologies to investigate the problem. There are now
active research programs to develop therapies to interfere with
fatty acid utilization in the failing heart [14], largely based on
animal experiments, and it cannot be ruled out that humans are
different.
Figure 1. Contributions of different substrates to myocardial
O2 consumption. Oxygen extraction ratios were summed and
adjusted to a total of 100%. Lower, white bar: sum of non-esterified
fatty acids and triacylglycerol (i.e. fatty acid oxidation); solid black,
glucose; diagonal hatched, lactate; cross-hatched, 3-hydroxybutyrate;
think solid line at top, pyruvate. Con, control group; HF, heart failure
group; DM, Type 2 diabetes group.
doi:10.1371/journal.pone.0007533.g001
Table 2. Fractional extraction (%) of non-esterified fatty acids
(NEFA), triacylglycerol, glucose, pyruvate, lactate and 3-
hydroxybutyrate across the heart in patients with heart
failure, controls and type 2 diabetes.
Heart failure
n=9
Control
n=10
Type 2 diabetes
n=5
NEFA 32683 3 682 9 65
Triacylglycerol 1.863.5 2.862.4 3.562.0
Glucose 2.763.5 3.862.0 2.360.8
Pyruvate 23631 28615 40637
Lactate 27616 27692 7 68
3-hydroxybutyrate 41683 2 622 3568
Values are mean6SD.
doi:10.1371/journal.pone.0007533.t002
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